215 related articles for article (PubMed ID: 23613095)
1. Prophylaxis of thromboembolic events in patients with nephrotic syndrome.
Pincus KJ; Hynicka LM
Ann Pharmacother; 2013 May; 47(5):725-34. PubMed ID: 23613095
[TBL] [Abstract][Full Text] [Related]
2. Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases.
Baetz BE; Spinler SA
Pharmacotherapy; 2008 Nov; 28(11):1354-73. PubMed ID: 18956996
[TBL] [Abstract][Full Text] [Related]
3. Survival of heparins, oral anticoagulants, and aspirin after the year 2010.
Fareed J; Hoppensteadt DA; Fareed D; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
Semin Thromb Hemost; 2008 Feb; 34(1):58-73. PubMed ID: 18393143
[TBL] [Abstract][Full Text] [Related]
4. Retrospective analysis of a novel regimen for the prevention of venous thromboembolism in nephrotic syndrome.
Medjeral-Thomas N; Ziaj S; Condon M; Galliford J; Levy J; Cairns T; Griffith M
Clin J Am Soc Nephrol; 2014 Mar; 9(3):478-83. PubMed ID: 24334865
[TBL] [Abstract][Full Text] [Related]
5. Assessment of bleeding risk of interventional techniques: a best evidence synthesis of practice patterns and perioperative management of anticoagulant and antithrombotic therapy.
Manchikanti L; Falco FJ; Benyamin RM; Caraway DL; Kaye AD; Helm S; Wargo BW; Hansen H; Parr AT; Singh V; Swicegood JR; Smith HS; Schultz DM; Malla Y; Hirsch JA
Pain Physician; 2013 Apr; 16(2 Suppl):SE261-318. PubMed ID: 23615893
[TBL] [Abstract][Full Text] [Related]
6. Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged?
Fareed J; Iqbal O; Cunanan J; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
Int Angiol; 2008 Jun; 27(3):176-92. PubMed ID: 18506123
[TBL] [Abstract][Full Text] [Related]
7. Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients.
Kanaan AO; Silva MA; Donovan JL; Roy T; Al-Homsi AS
Clin Ther; 2007 Nov; 29(11):2395-405. PubMed ID: 18158080
[TBL] [Abstract][Full Text] [Related]
8. Direct thrombin inhibitors for anticoagulation.
Nutescu EA; Wittkowsky AK
Ann Pharmacother; 2004 Jan; 38(1):99-109. PubMed ID: 14742803
[TBL] [Abstract][Full Text] [Related]
9. Fondaparinux for prevention of venous thromboembolism in major orthopedic surgery.
Tran AH; Lee G
Ann Pharmacother; 2003 Nov; 37(11):1632-43. PubMed ID: 14565815
[TBL] [Abstract][Full Text] [Related]
10. Rivaroxaban: an oral factor Xa inhibitor.
Thomas TF; Ganetsky V; Spinler SA
Clin Ther; 2013 Jan; 35(1):4-27. PubMed ID: 23328267
[TBL] [Abstract][Full Text] [Related]
11. Fondaparinux for thromboembolic treatment and prophylaxis of heparin-induced thrombocytopenia.
Efird LE; Kockler DR
Ann Pharmacother; 2006; 40(7-8):1383-7. PubMed ID: 16788093
[TBL] [Abstract][Full Text] [Related]
12. The potential role of new oral anticoagulants in the prevention and treatment of thromboembolism.
Mavrakanas T; Bounameaux H
Pharmacol Ther; 2011 Apr; 130(1):46-58. PubMed ID: 21185864
[TBL] [Abstract][Full Text] [Related]
13. Responsible, Safe, and Effective Use of Antithrombotics and Anticoagulants in Patients Undergoing Interventional Techniques: American Society of Interventional Pain Physicians (ASIPP) Guidelines.
Kaye AD; Manchikanti L; Novitch MB; Mungrue IN; Anwar M; Jones MR; Helander EM; Cornett EM; Eng MR; Grider JS; Harned ME; Benyamin RM; Swicegood JR; Simopoulos TT; Abdi S; Urman RD; Deer TR; Bakhit C; Sanapati M; Atluri S; Pasupuleti R; Soin A; Diwan S; Vallejo R; Candido KD; Knezevic NN; Beall D; Albers SL; Latchaw RE; Prabhakar H; Hirsch JA
Pain Physician; 2019 Jan; 22(1S):S75-S128. PubMed ID: 30717501
[TBL] [Abstract][Full Text] [Related]
14. Dabigatran: new drug. Continue to use heparin, a better-known option.
Prescrire Int; 2009 Jun; 18(101):97-9. PubMed ID: 19637411
[TBL] [Abstract][Full Text] [Related]
15. The role of apixaban for venous and arterial thromboembolic disease.
Prom R; Spinler SA
Ann Pharmacother; 2011 Oct; 45(10):1262-83. PubMed ID: 21954450
[TBL] [Abstract][Full Text] [Related]
16. Low-molecular-weight heparin (LMWH) in the treatment of thrombosis.
Holzheimer RG
Eur J Med Res; 2004 Apr; 9(4):225-39. PubMed ID: 15210403
[TBL] [Abstract][Full Text] [Related]
17. [Complications and risks associated with an anticoagulation therapy combining low molecular weight heparin and Warfarin after total replacement of large joints--our experience].
Míka P; Behounek J; Skoták M; Nevsímal L
Acta Chir Orthop Traumatol Cech; 2004; 71(4):237-44. PubMed ID: 15456102
[TBL] [Abstract][Full Text] [Related]
18. New and emerging anticoagulant therapy for atrial fibrillation and acute coronary syndrome.
Davis EM; Packard KA; Knezevich JT; Campbell JA
Pharmacotherapy; 2011 Oct; 31(10):975-1016. PubMed ID: 21950643
[TBL] [Abstract][Full Text] [Related]
19. Intermittent nondaily dosing strategies in patients with previous statin-induced myopathy.
Keating AJ; Campbell KB; Guyton JR
Ann Pharmacother; 2013 Mar; 47(3):398-404. PubMed ID: 23482733
[TBL] [Abstract][Full Text] [Related]
20. Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings.
Nutescu EA; Spinler SA; Wittkowsky A; Dager WE
Ann Pharmacother; 2009 Jun; 43(6):1064-83. PubMed ID: 19458109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
